Leading CRO Appointed for Phase 2 Crohn's Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This appointment marks a significant operational milestone for the company as it progresses towards trial initiation by the end of the year. Southern Star Research will manage clinical sites and logistics for the trial, which aims to evaluate the company's StemSmart™ technology. The trial targets a severe form of Crohn's disease that currently has limited treatment options available.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- 2026 Annual Report & Appendix 4E
- Remarkable Results from Patients treated with StemSmart
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Clinical Results Achieved under Special Access
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals